1. Durvalumab-associated vasculitis presenting as ‘the blue toe syndrome’
- Author
-
Dan Xu, David Prentice, Shivangi Gupta, and Jane Hadfield
- Subjects
Vasculitis ,medicine.medical_specialty ,Lung Neoplasms ,Durvalumab ,Blue Toe Syndrome ,Prednisolone ,Case Report ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Humans ,Medicine ,Stage (cooking) ,Lung cancer ,Glucocorticoids ,Pneumonitis ,Aged, 80 and over ,030203 arthritis & rheumatology ,business.industry ,Antibodies, Monoclonal ,General Medicine ,Livedo racemosa ,medicine.disease ,Dermatology ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Durvalumab is a selective, high-affinity human immunoglobulin monoclonal antibody in a class called check point inhibitors, that blocks PD-L1 on tumour cells. Despite clinical success in increasing progression-free survival rates in patients with stage III non-small-cell lung cancer, durvalumab has been associated with immune-related side effects such as pneumonitis and colitis. We present a case of an 84-year-old woman with acral vasculitis presenting as blue toe syndrome, associated with prolonged use of durvalumab. After 1 year of fortnightly durvalumab therapy postchemoradiation therapy, the patient came in with a left blue big toe, and later developed bilateral livedo racemosa. The diagnosis of durvalumab-associated vasculitis was made and treatment with prednisolone was started with clinical improvement.
- Published
- 2020
- Full Text
- View/download PDF